Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Neoplasms, Second Primary × icotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5 NSCLC 2 Neoplasms, Second Primary 1 Lung Neoplasms 1 Adenocarcinoma 1

Interventions

sacubitril and valsartan sodium hydrate drug combination 1 icotinib 1 Thalidomide 1 Megestrol Acetate 1 Isotretinoin 1 Drug Therapy 1 Doxycycline 1 Docetaxel 1 Carboplatin 1 Antineoplastic Agents 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02283424 2014-11-05

Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Chinese PLA General Hospital

Phase 4 Unknown

Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡